Biolingus

Executive Summary

Biolingus is a Swiss biotech pioneering a sublingual delivery platform for biologics and vaccines, aiming to replace injections with patient-friendly tablets or films. Founded in 2016 and based in Zug, the company addresses key challenges in biologic administration: invasiveness, stability, and patient compliance. Its proprietary technology enables oral delivery of large molecules, potentially transforming treatment paradigms across multiple therapeutic areas. While still private and early-stage, Biolingus's approach aligns with the growing demand for needle-free alternatives. The company's progress depends on successful preclinical and clinical validation, as no publicly disclosed pipeline stages are available. With the increasing focus on non-invasive drug delivery, Biolingus occupies a strategic niche, though execution risks remain high. The sublingual route offers advantages over traditional oral delivery by bypassing first-pass metabolism and gastrointestinal degradation, making it attractive for biologics. If successful, the platform could unlock significant market opportunities in diabetes, autoimmune diseases, and vaccines.

Upcoming Catalysts (preview)

• 2027Announcement of lead candidate advancement to clinical trials40% success
• 2027Partnership with a large pharma for co-development or licensing30% success
• 2026Completion of a significant funding round (Series A or B)50% success